Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 175 of 335

Guidance and quality standards awaiting development
Title	Type
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [TSID12243]	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]	Technology appraisal guidance
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]	Technology appraisal guidance
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]	Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Managing symptoms with an uncertain cause	Quality standard
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Health technology evaluation
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]	Technology appraisal guidance
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]	Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730]	Technology appraisal guidance
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance

Results per page

10
25
50
All